课题基金 / 基金详情

Role of T cells in recovery from bluetongue virus infection in calves

Role of T cells in recovery from bluetongue virus infection in calves
T 细胞在犊牛蓝舌病毒感染恢复中的作用
批准号:
BB/H003258/1
负责人:
Geraldine Taylor
金额:
$25.11万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2010
资助国家:
英国
项目状态:
已结题
起止时间:
2010 至 --

项目摘要

项目成果

Geraldine Taylor的其他基金

相似基金

相关文献

中文摘要
翻译
蓝舌病是由蓝舌病毒(BTV)引起的绵羊、牛、山羊和鹿的一种重要的经济传染病。感染BTV的动物会出现发热、嘴唇、嘴巴、鼻道和眼睑发红和肿胀,迅速丧失机能,出现肌肉退化和跛行,并可能死于该病。至少有24种不同类型的BTV,直到最近,该疾病主要局限于非洲、亚洲、美洲和澳大利亚的区域。然而,由于气候变化和欧洲气候变暖,感染btv的蠓传播到南欧,2006年在一些北欧国家爆发了蓝舌病。这是首次在北欧发现BTV, 2007年8月,该病毒传播到英国。在2007年底/ 2008年初,BTV血清型1抵达法国南部,其分布与BTV-8重叠。这增加了这些病毒株交换基因的可能性。这可能会增强BTV-1混合后代株向北传播的能力,并增加第二种血清型(BTV-1)在北欧和英国的威胁。2008年期间,在荷兰和德国发现了第三种病毒BTV-6。在最近受感染的国家采取的控制措施包括限制动物流动(这会产生重大的经济影响)和接种疫苗。BTV疫苗接种的目的是预防临床疾病;防止新的动物被感染,并允许动物从感染地区安全移动。自愿接种灭活BTV-8疫苗于2008年引入英国。灭活(改良活)和灭活BTV疫苗都已被使用,但它们都有一些缺点。主要的问题是,由一种血清型的BTV诱导的免疫只能防止同一血清型的感染。改良活病毒疫苗生产成本低廉,单次注射后可产生保护性免疫,可在某些易感品种的绵羊中诱发临床疾病,并有可能通过蠓传播,并有可能变回可引起严重疾病的病毒。虽然灭活疫苗如果生产得当是安全的,但很难确定动物是否被感染或接种过疫苗;生产成本高,而且不同品种的动物对疫苗接种的反应有明显差异。由于目前的BTV-8灭活疫苗完全是针对BTV血清型的,因此需要开发一种新的疫苗,以防止BTV-1和BTV-6对英国的潜在威胁,从而增加实验室诊断和疫苗分发的成本。诱导针对多种不同BTV血清型的免疫反应可能在开发更广泛的交叉保护BTV疫苗中发挥重要作用。虽然BTV抗体往往是血清型特异性的,但有证据表明细胞介导的免疫(T细胞)更具交叉反应性。然而,T细胞对BTV的保护作用尚不清楚。在这个项目中,我们将研究细胞介导免疫在牛BTV感染恢复中的作用。这些研究的发现将确定负责保护的免疫反应的要素,这些信息将有助于开发新的BT疫苗策略。
英文摘要
Bluetongue (BT) is an economically important infectious disease of sheep, cattle, goats and deer caused by bluetongue virus (BTV), which is spread by types of biting midges. Animals infected with BTV develop fever, reddening and swelling of the lips, mouth, nasal passages and eyelids, lose condition rapidly, develop muscle degeneration and lameness and may die from the disease. There are at least 24 different types of BTV and, until recently, the disease was largely confined to regions within Africa, Asia, the Americas and Australia. However, as a result of climate change and warmer weather in Europe, BTV-infected midges spread into southern Europe and in 2006 an outbreak of bluetongue occurred in some northern European countries. This was the first time that BTV has been known in northern Europe and in August 2007, the virus spread to the UK. During late 2007/early 2008 BTV serotype 1 arrived in southern France and its distribution overlaps with BTV-8. This raises the possibility that these strains of virus will exchange genes. This may enhance the ability of BTV-1 mixed progeny strains to spread northwards and increase the threat of a second serotype (BTV-1) in northern Europe and the UK. During 2008, a third strain of virus, BTV-6, was detected in the Netherlands and Germany. Control measures in recently infected countries include restrictions on animal movement, which have a significant economic impact, and vaccination. The aims of BTV vaccination are to prevent clinical disease; prevent new animals becoming infected and to allow the safe movement of animals from infected areas. Voluntary vaccination with an inactivated BTV-8 vaccine was introduced into the UK in 2008. Both disabled (modified live) and killed BTV vaccines have been used, but they both have a number of shortcomings. The main problem is that immunity induced by one serotype of BTV only protects against infection with the same serotype. Modified live virus vaccines, which are cheap to produce and generate protective immunity after a single dose, can induce clinical disease in certain susceptible breeds of sheep and have the potential to be spread by midges with the possibility of changing back to a virus that can cause severe disease. Although killed vaccines are safe if properly produced, it is difficult to determine whether animals have been infected or vaccinated; production costs are high and there are marked differences in the response of different breeds of animals to vaccination. Since the current inactivated BTV-8 vaccines are entirely BTV serotype specific, a new vaccine would need to be developed to protect against the potential threat to the UK of BTV-1 and BTV-6, increasing the cost of laboratory diagnosis and distribution of the vaccines. Induction of immune responses that protect against a number of different BTV serotypes could play a significant part in the development of a more widely cross-protective BTV vaccine. Whereas antibody to BTV tends to be serotype-specific, there is evidence that cell-mediated immunity (T cells) is more cross-reactive. However, the role of T cells in protection against BTV is not clear. In this project, we will investigate the role of cell-mediated immunity in recovery from BTV infection in cattle. The findings from these studies will identify elements of the immune response that are responsible for protection and this information will facilitate the development of novel BT vaccine strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-clinical development of a simian adenovirus vectored respiratory syncytial virus (RSV) vaccine
  • 批准号:
    MR/J014648/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $68.3万
  • 财政年份:
    2012
  • 负责人:
    Geraldine Taylor
  • 依托单位:
Development and comparative evaluation of three new generation BRSV DIVA vaccines and a corresponding DIVA test
  • 批准号:
    BB/I017216/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $50.83万
  • 财政年份:
    2011
  • 负责人:
    Geraldine Taylor
  • 依托单位:
Immune inductor and effector sites in the upper airways of cattle and influence of site of antigen expression on induction of mucosal immunity. THIS G
  • 批准号:
    BB/H531135/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $14.97万
  • 财政年份:
    2009
  • 负责人:
    Geraldine Taylor
  • 依托单位:
Immune inductor and effector sites in the upper airways of cattle and influence of site of antigen expression on induction of mucosal immunity
  • 批准号:
    BB/D001536/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $40.96万
  • 财政年份:
    2006
  • 负责人:
    Geraldine Taylor
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
库否细胞(Kupffer cells)受体PirB/LILRB2在非酒精性脂肪性肝炎中的作用及机制研究
  • 批准号:
    82470907
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2024
  • 负责人:
    余学锋
  • 依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位: